Cerebral Ischemia
Cerebral ischemia is a condition characterized by insufficient blood flow to the brain, leading to a deprivation of essential oxygen and nutrients required for brain cell function. This lack of adequate blood supply can result in cellular dysfunction, damage, and potentially permanent brain injury, impacting various neurological processes.
At a biological level, the interruption of blood flow in cerebral ischemia disrupts normal cellular metabolism, initiating a cascade of events that can lead to neuronal injury or death. Genetic factors are increasingly recognized for their influence on an individual’s susceptibility to and the outcome of ischemic events. Genome-wide association studies (GWAS) are utilized to identify single nucleotide polymorphisms (SNPs) and other genetic variants associated with brain conditions. For example, common genetic variants have been found to be associated with brain microbleeds (BMBs) and white matter hyperintensities (WMH)[1], which are markers of cerebral small vessel disease, a condition often linked to ischemic damage.
Cerebral ischemia is the primary mechanism underlying ischemic stroke, a leading cause of disability and mortality worldwide. Its clinical manifestations can range from transient neurological deficits to severe, permanent impairments in motor function, cognition, and speech. Understanding the genetic predispositions to cerebral ischemia and its related pathologies, such as BMBs and WMH[1], is crucial for improving risk assessment, enhancing diagnostic strategies, and guiding the development of more personalized therapeutic approaches.
The significant burden of cerebral ischemia on individuals and healthcare systems underscores its considerable social importance. It contributes to long-term care needs, reduced quality of life for those affected, and substantial economic costs. By elucidating the genetic underpinnings of cerebral ischemia, researchers aim to improve prevention strategies, enhance early diagnosis, and develop more effective treatments, ultimately reducing the profound societal impact of this debilitating condition.
Limitations
Section titled “Limitations”Methodological and Statistical Considerations
Section titled “Methodological and Statistical Considerations”Studies investigating the genetic architecture of cerebral ischemia often face challenges related to sample size and statistical power. Many large-scale genome-wide association studies (GWAS) still operate with relatively modest sample sizes for complex traits, which can limit their power to detect genetic variants with small effect sizes, particularly for conditions with low incidence rates such as cerebral venous thrombosis[2], [3], [4]. This limitation suggests that current research has only identified a moderate proportion of the genetic variants contributing to the overall heritability of these diseases [2]. Consequently, findings frequently necessitate extensive replication in independent cohorts to confirm their validity and mitigate potential effect-size inflation, a common issue in genetic association studies[5], [3].
The complexity of study design and analytical methodologies also presents significant hurdles. For instance, meta-analyses, while powerful for combining data, can struggle with confounding factors such as age being intertwined with specific cohorts, making it difficult to isolate the precise impact of age on observed genetic associations [3]. Moreover, the application of stringent genome-wide significance thresholds, including Bonferroni correction or suggestive significance levels, is essential for controlling false positives but may inadvertently lead to missing true genetic associations with subtle effects [6], [1], [3]. The high-dimensional nature of significant association pairs observed in advanced analyses like Mendelian randomization further underscores the analytical challenges in accurately interpreting intricate genetic relationships [7].
Phenotypic Heterogeneity and Generalizability
Section titled “Phenotypic Heterogeneity and Generalizability”The diverse range of phenotypes associated with cerebral ischemia, including brain microbleeds, amyloid deposition, cerebrospinal fluid (CSF) biomarker levels, and various measures of cortical morphology and brain structure, contributes to significant phenotypic heterogeneity across studies[1], [4], [8], [9], [10], [11]. While allowing for the identification of brain-structure-specific associations, this variability in phenotype definition and measurement can complicate the integration and comparison of findings across different research efforts [3]. The presence of phenotypic correlations between distinct structural changes also suggests that certain genetic variants might exert broader, global effects, indicating that combining multiple phenotypes could be a more effective strategy for capturing comprehensive genetic influences [3].
Another critical limitation pertains to the generalizability of research findings across diverse populations. Many large-scale genetic studies, including GWAS, are often conducted in populations of specific ancestries, such as Japanese cohorts or those predominantly of European descent [5], [12]. This demographic bias can restrict the applicability of discovered genetic associations to other ancestral groups, such as Black adults, due to variations in linkage disequilibrium patterns, allele frequencies, and the interplay between genes and environmental factors [13], [12]. Although efforts to create cross-population atlases of genetic associations are underway, ensuring robust and equitable findings across the global population remains a significant challenge, potentially leading to an incomplete understanding of genetic risk factors in underrepresented groups [12].
Incomplete Genetic Architecture and Unaccounted Factors
Section titled “Incomplete Genetic Architecture and Unaccounted Factors”Despite extensive research, a substantial proportion of the heritability for complex traits like cerebral ischemia remains unexplained by currently identified genetic variants[2]. Even with comprehensive GWAS efforts, only moderate proportions of the genetic contribution to disease risk have been elucidated, suggesting the involvement of numerous additional variants with individually small effects, rare variants, or complex gene-gene and gene-environment interactions that are yet to be fully understood[2]. The ongoing utility of protein quantitative trait loci (pQTLs) for prioritizing candidate genes at established risk loci highlights the continuous need to map the complete proteo-genomic convergence of human diseases to uncover these missing genetic components [14].
Furthermore, residual heterogeneity and unmeasured confounders can still influence study outcomes, even in analyses employing advanced statistical models. For example, while some studies account for factors such as intracranial volume, the observed associations with brain changes over time may be small, indicating that other influential, unmeasured factors are likely at play [3]. The intricate interplay between genetic predispositions and environmental factors, including lifestyle and socioeconomic determinants, is not always fully captured by current research designs. This leaves gaps in the understanding of the complete etiological landscape of cerebral ischemia, emphasizing the need for continued investigation into complex gene-environment interactions to achieve a more comprehensive understanding of the disease’s multifaceted origins.
Variants
Genetic variations significantly influence an individual’s susceptibility and response to cerebral ischemia by affecting genes involved in vascular health, inflammation, and tissue repair. The variantrs2107595 is linked to both the HDAC9 and TWIST1 genes, with HDAC9 (Histone Deacetylase 9) encoding an enzyme crucial for regulating gene expression through chromatin remodeling [15]. Genome-wide association studies have identified variants in HDAC9, including rs2107595 , as being associated with large vessel ischemic stroke, highlighting its role in cerebral vascular disease by potentially impacting epigenetic control of genes vital for blood vessel integrity[16]. Furthermore, TWIST1, a transcription factor essential for embryonic development and angiogenesis, suggests that variations near it could influence vascular remodeling and repair following ischemic injury. Another key variant, rs276472 , is associated with the IL20RA and IL22RA2 genes, both central to immune and inflammatory responses; IL20RA encodes a receptor subunit for interleukins-20 and -24, while IL22RA2 codes for a soluble protein that antagonizes interleukin-22. Variations like rs276472 could therefore modulate these cytokine pathways, influencing the delicate balance of neuroinflammation and tissue repair in the brain after an ischemic event.
Operational Definition and Measurement of Cerebral Blood Flow
Section titled “Operational Definition and Measurement of Cerebral Blood Flow”Cerebral blood flow (CBF) is operationally defined and quantified through advanced imaging techniques to assess the perfusion of the brain. Research employs 2D phase-contrast magnetic resonance imaging (MRI) angiography, utilizing a 2D gradient-echo phase-contrast sequence, to precisely measure blood flow . Furthermore, “cerebral blood flow” (CBF) is a fundamental physiological measure, with reduced flow being a direct indicator of ischemia; its heritability underscores individual variations in vascular efficiency [17]. The presence of “brain microbleeds” and “brain arteriolosclerosis” are significant findings, representing objective signs of small vessel disease within the brain, which are common precursors to ischemic events and can be identified through diagnostic imaging[1]. These objective measures provide diagnostic value by identifying individuals at risk or showing evidence of prior cerebrovascular damage, even in the absence of overt acute symptoms.
Systemic Biomarkers and Cardiovascular Correlations
Section titled “Systemic Biomarkers and Cardiovascular Correlations”Beyond direct cerebral observations, systemic indicators offer insights into the overall risk profile for cerebral ischemia, particularly through cardiovascular health. Analysis of the “plasma proteome,” which involves studying the complete set of proteins in blood plasma, can provide novel insights into cardiovascular disease[13]. Cardiovascular disease is a major risk factor for cerebral ischemia, and changes in specific proteins within the plasma proteome could serve as potential biomarkers for heightened risk. Such objective proteomic measurements contribute to a comprehensive understanding of an individual’s susceptibility, offering prognostic indicators that can complement direct brain imaging findings in assessing the likelihood of ischemic events[13].
Heterogeneity in Cerebrovascular Characteristics
Section titled “Heterogeneity in Cerebrovascular Characteristics”The presentation and underlying susceptibility to cerebral ischemia are highly variable among individuals, reflecting significant “inter-individual variation” in cerebrovascular characteristics. Genetic studies have identified numerous genetic loci associated with traits like “cortical morphology” and “cerebral blood flow,” highlighting the diverse genetic architecture influencing brain health and vulnerability to ischemia[9]. This phenotypic diversity extends to demographic groups, with research exploring the “plasma proteome” in specific populations, such as “Black Adults,” to uncover unique insights into cardiovascular disease, thereby suggesting potential “age-related changes” or “sex differences” in risk factor profiles that could influence ischemic presentation[13]. Recognizing this inherent heterogeneity is vital for understanding diverse presentation patterns, refining differential diagnoses, and developing more personalized strategies for prevention and management.
Causes of Cerebral Ischemia
Section titled “Causes of Cerebral Ischemia”Cerebral ischemia, a condition resulting from insufficient blood flow to the brain, arises from a complex interplay of genetic predispositions, underlying vascular pathologies, and systemic health factors. Research indicates that an individual’s vulnerability to ischemic events is significantly shaped by inherited traits that affect cerebrovascular integrity and function.
Genetic Predisposition to Vascular Fragility and Thrombosis
Section titled “Genetic Predisposition to Vascular Fragility and Thrombosis”An individual’s genetic makeup plays a substantial role in determining susceptibility to cerebral ischemia, with various inherited variants contributing to the fragility and function of the cerebrovascular system. Common genetic variants have been associated with markers of cerebral small vessel disease, such as brain microbleeds (BMBs) and white matter hyperintensities (WMH)[1]. These genetic influences underscore a polygenic basis for the structural integrity of brain vasculature, where multiple genes collectively increase the risk of developing conditions that restrict blood flow.
Beyond common variants, specific genetic loci have been identified as contributing to the risk of acute ischemic events, including cerebral venous thrombosis, a condition characterized by blood clot formation in the brain’s venous sinuses that can impede blood circulation [2]. While genome-wide association studies (GWAS) have uncovered some of these loci, the collective impact of numerous genetic variants on disease heritability suggests a complex genetic architecture[2]. Furthermore, inherited mutations, such as a missense mutation in the COL22A1 gene, have been linked to intracranial aneurysms, which can lead to thrombotic complications or rupture, contributing to ischemic brain injury [17]. Genetic factors also contribute to the development of brain arteriolosclerosis, a condition involving the hardening and narrowing of small brain arteries that impairs blood supply and heightens ischemia risk [18].
Genetic Influences on Brain Structure and Hemodynamics
Section titled “Genetic Influences on Brain Structure and Hemodynamics”Genetic factors also exert their influence by affecting fundamental aspects of brain structure and the dynamics of cerebral blood flow, which are critical for maintaining adequate oxygen and nutrient supply to brain tissues. Studies have identified numerous genetic loci associated with cortical morphology, including variants that impact the total surface area and mean cortical thickness of the brain [9]. These genetically determined structural characteristics can influence the brain’s overall resilience and capacity to withstand periods of reduced blood supply, potentially modulating the extent of damage during an ischemic event.
Moreover, the regulation of cerebral blood flow itself demonstrates significant heritability, indicating a strong genetic component in its control [17]. Genetic variations can affect the efficiency with which blood is supplied to brain regions, influencing the brain’s ability to adapt to metabolic demands or compromised perfusion. Differences in these genetic factors may contribute to an individual’s baseline cerebral perfusion levels, making some individuals more vulnerable to ischemia when other risk factors are present.
Systemic Comorbidities and Proteomic Pathways
Section titled “Systemic Comorbidities and Proteomic Pathways”Cerebral ischemia is often compounded by systemic comorbidities, many of which are influenced by genetic factors and manifest through specific proteomic pathways. Cardiovascular disease, a primary risk factor for cerebral ischemia, is known to have complex genetic underpinnings that are reflected in the levels of various circulating proteins[13]. Whole genome sequence analysis of the plasma proteome provides insights into how genetic variants can influence protein abundance, thereby affecting cardiovascular health and, consequently, cerebral perfusion[13].
The identification of protein quantitative trait loci (pQTLs) further clarifies how genetic variations impact the levels of specific proteins, offering a mechanistic link between genetic predisposition and disease states relevant to cerebral ischemia[14]. These proteo-genomic connections highlight how genetic factors contribute to systemic conditions that indirectly elevate the risk of cerebral ischemia by influencing processes such as coagulation, inflammation, or overall vascular health. For example, conditions like cerebral small vessel disease, characterized by brain microbleeds and white matter hyperintensities, are not only linked to specific genetic variants but also represent a broader systemic vascular pathology that directly increases ischemia risk[1].
Biological Background
Section titled “Biological Background”Cerebral ischemia, a condition arising from insufficient blood flow to the brain, leads to a deprivation of oxygen and nutrients critical for neuronal function and survival. Understanding the multifaceted biological processes underlying cerebral ischemia involves examining vascular health, genetic predispositions, molecular pathways, and systemic influences that collectively contribute to its development and progression. Research into these areas helps elucidate the complex interplay of factors that can disrupt cerebral homeostasis and lead to brain injury.
Vascular Pathophysiology and Cerebral Blood Flow
Section titled “Vascular Pathophysiology and Cerebral Blood Flow”The health and function of the brain’s vasculature are paramount in preventing cerebral ischemia. Conditions that impair the integrity or patency of cerebral blood vessels directly increase the risk of ischemic events. For instance, brain arteriolosclerosis, a disease affecting small arteries in the brain, has been investigated for its genetic associations, highlighting a key pathophysiological process that can restrict blood flow[18]. Similarly, brain microbleeds, small hemorrhages often linked to small vessel disease, represent another vascular vulnerability that can predispose the brain to ischemic injury[1]. Furthermore, the obstruction of venous outflow, as seen in cerebral venous thrombosis, can also lead to cerebral ischemia or infarction, emphasizing that both arterial and venous systems play critical roles in maintaining adequate cerebral perfusion[2]. The overall cerebral blood flow itself is a heritable trait, with genetic factors influencing its regulation and therefore susceptibility to ischemic conditions [17].
Genetic Architecture of Brain and Vascular Traits
Section titled “Genetic Architecture of Brain and Vascular Traits”Genetic mechanisms play a significant role in an individual’s susceptibility to cerebral ischemia by influencing various brain and vascular traits. Genome-wide association studies (GWAS) have identified specific genetic loci associated with susceptibility to conditions like cerebral venous thrombosis, indicating inherited predispositions to vascular pathologies that can lead to ischemia[2]. Beyond direct vascular diseases, genetic variants are also linked to structural aspects of the brain, such as cortical morphology, with hundreds of unique genetic loci identified as associated with these features [9]. These genetic correlations with cortical structure suggest that inherited factors can influence the brain’s physical characteristics, which may in turn impact its resilience or vulnerability to ischemic insult [19]. The intricate regulatory networks governed by these genetic elements can affect the development and maintenance of both brain tissue and its supporting vascular network.
Proteomic Signatures and Systemic Risk Factors
Section titled “Proteomic Signatures and Systemic Risk Factors”Key biomolecules, particularly proteins, serve as crucial mediators and indicators of health and disease, including those relevant to cerebral ischemia. Studies mapping the genomic atlas of the human plasma proteome have revealed how genetic variations can influence the levels of circulating proteins, which in turn can impact various physiological processes[20]. This proteo-genomic convergence helps in understanding how genetic predispositions translate into altered protein functions that contribute to disease mechanisms[14]. For example, insights from the whole genome sequence analysis of the plasma proteome have provided novel understandings into cardiovascular disease, a major systemic risk factor for cerebral ischemia[13]. Conditions like hypertension (HTN) and diabetes mellitus (DM) are significant homeostatic disruptions that exacerbate vascular damage and increase ischemia risk, and their biological underpinnings often involve complex interactions between genetic factors and proteomic profiles[18].
Cellular and Molecular Impacts on Brain Structure and Function
Section titled “Cellular and Molecular Impacts on Brain Structure and Function”At the cellular and molecular level, the consequences of impaired vascular health and genetic predispositions manifest as disruptions to normal brain function and structure. The molecular and cellular pathways affected by ischemia involve complex signaling cascades and metabolic processes that are critical for cell survival. While the acute cellular response to ischemia involves processes like excitotoxicity and inflammation, the long-term impact of chronic hypoperfusion or recurrent micro-injuries can lead to subtle but significant changes in cellular functions and regulatory networks. Genetic factors influencing cortical morphology suggest a role for inherited mechanisms in shaping the brain’s structural components, which could influence how brain tissue responds to or recovers from ischemic events [9]. These genetic and molecular underpinnings contribute to the overall resilience or vulnerability of brain cells to oxygen and nutrient deprivation, ultimately affecting cognitive and neurological outcomes.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Cerebral ischemia, characterized by insufficient blood flow to the brain, involves complex pathways and mechanisms influenced by genetic predispositions and molecular regulation. These mechanisms span from the genetic control of brain structure and vascular health to the dynamic interplay of proteins that govern metabolic and signaling responses. Understanding these integrated pathways is crucial for identifying the roots of susceptibility and potential therapeutic targets.
Genetic Architectures Influencing Cerebrovascular Health and Brain Structure
Section titled “Genetic Architectures Influencing Cerebrovascular Health and Brain Structure”Genetic variations play a significant role in shaping the brain’s susceptibility to ischemic events by influencing underlying structural and vascular traits. Genome-wide association studies (GWAS) have identified numerous genetic loci associated with cortical morphology, indicating that inherited factors contribute to variations in brain structure [9]. These genetic influences on cortical structure and longitudinal changes in brain structure across the lifespan can predispose individuals to different levels of resilience or vulnerability to ischemic injury, suggesting a foundational role for gene regulation in maintaining brain integrity [3]. Such genetic predispositions can affect neuronal density, connectivity, and overall brain architecture, which are critical determinants of post-ischemic outcomes.
Beyond gross brain structure, genetic mechanisms also directly impact cerebrovascular health, a primary determinant of ischemia risk. Common genetic variants have been linked to conditions such as brain microbleeds and arteriolosclerosis, highlighting specific genetic regulatory mechanisms that govern vascular integrity [1]. Furthermore, genome-wide association studies have explored the heritability and genetic associations of cerebral blood flow, identifying loci that influence this vital physiological parameter [17]. Dysregulation of these genetically controlled vascular pathways can lead to compromised blood supply, increased vessel fragility, or impaired autoregulation, thereby significantly elevating the risk for cerebral ischemia.
Proteomic Signatures and Metabolic Dysregulation
Section titled “Proteomic Signatures and Metabolic Dysregulation”The proteome, particularly in plasma, serves as a dynamic readout of metabolic health and disease processes relevant to cerebral ischemia. Genetic variations influence the levels and modifications of a vast array of proteins, establishing a proteo-genomic convergence that can impact disease susceptibility[14]. For instance, whole-genome sequence analysis of the plasma proteome has provided insights into cardiovascular disease, a major risk factor for ischemia, by identifying proteins involved in metabolic regulation and flux control[13]. These proteomic signatures can reflect underlying dysregulations in energy metabolism, biosynthesis, and catabolic pathways, which are critical for neuronal survival and function during ischemic stress.
Metabolic pathways are profoundly impacted during ischemia, and proteomic studies help identify key players in this response. Proteins involved in glycolysis, oxidative phosphorylation, and lipid metabolism are subject to both genetic regulation and post-translational modifications that can alter their activity and abundance, thereby modulating cellular energy status [20]. Dysregulation of these metabolic pathways, as indicated by altered proteomic profiles, can lead to insufficient ATP production, accumulation of toxic metabolites, and impaired cellular repair mechanisms, exacerbating ischemic damage. Understanding these protein-level changes and their genetic underpinnings offers potential therapeutic targets for restoring metabolic homeostasis in the context of ischemia[14].
Molecular Signaling in Vascular Integrity and Dysregulation
Section titled “Molecular Signaling in Vascular Integrity and Dysregulation”Intracellular signaling cascades and receptor activation play crucial roles in maintaining vascular integrity and responding to injury, with dysregulation contributing to ischemic pathology. Genetic loci associated with susceptibility to cerebral venous thrombosis, for instance, point to specific molecular pathways that govern coagulation and vascular wall function [2]. These pathways involve a complex interplay of receptor activation, downstream signaling molecules, and transcription factor regulation that collectively dictate endothelial cell survival, proliferation, and barrier function. Aberrations in these signaling networks can lead to thrombus formation or vascular remodeling, directly increasing ischemia risk.
The development of conditions like brain arteriolosclerosis, a significant contributor to cerebral ischemia, also involves specific molecular signaling pathways and regulatory mechanisms[18]. Genetic influences on the proteome, as revealed by studies mapping proteins in brain, CSF, and plasma, can highlight key proteins involved in vascular smooth muscle cell function, inflammation, and extracellular matrix remodeling[21]. Post-translational modifications of these proteins, along with their allosteric control, can modulate the activity of critical enzymes and structural components, leading to arterial stiffening and luminal narrowing, thereby impairing cerebral blood flow and increasing vulnerability to ischemia.
Systems-Level Integration of Genetic and Molecular Networks
Section titled “Systems-Level Integration of Genetic and Molecular Networks”The pathogenesis of cerebral ischemia arises from a complex systems-level integration of genetic and molecular networks, rather than isolated pathway dysfunctions. Multivariate statistical methods are essential to unravel the intricate interplay between numerous genetic loci and their cumulative effects on traits like cortical morphology, which represent emergent properties of these integrated networks[9]. This pathway crosstalk involves feedback loops and hierarchical regulation, where genetic variants influence upstream regulatory elements that, in turn, modulate the activity of multiple downstream signaling and metabolic pathways. Understanding these network interactions is crucial for comprehending the holistic susceptibility to ischemic brain injury.
The convergence of proteomic and genomic data further elucidates how different molecular pathways interact at a systems level to influence disease-relevant mechanisms. Studies mapping the proteo-genomic landscape of human diseases, including those related to cardiovascular health, reveal how genetic predispositions manifest through altered protein expression and function across various biological systems[14]. These network interactions demonstrate how dysregulation in one pathway, such as those governing vascular integrity, can propagate through interconnected systems, impacting energy metabolism or neuroinflammation, ultimately contributing to the overall pathology of cerebral ischemia. Identifying these integrated networks offers a more comprehensive approach to identifying compensatory mechanisms and novel therapeutic targets.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs2107595 | HDAC9 - TWIST1 | coronary artery disease Ischemic stroke pulse pressure measurement stroke systolic blood pressure |
| rs276472 | IL20RA - IL22RA2 | cerebral ischemia transient ischemic attack |
Frequently Asked Questions About Cerebral Ischemia
Section titled “Frequently Asked Questions About Cerebral Ischemia”These questions address the most important and specific aspects of cerebral ischemia based on current genetic research.
1. My family has a history of strokes. Does that mean I’m at higher risk?
Section titled “1. My family has a history of strokes. Does that mean I’m at higher risk?”Yes, genetic factors play a significant role in your susceptibility to conditions like cerebral ischemia, which often leads to stroke. If close family members have had strokes, you might have inherited certain genetic predispositions that increase your personal risk. Understanding these genetic links helps doctors assess your risk more accurately.
2. If I have a genetic risk, can healthy habits still protect me?
Section titled “2. If I have a genetic risk, can healthy habits still protect me?”Absolutely, yes. While your genes influence your baseline susceptibility, environmental factors and lifestyle choices, like maintaining healthy habits, interact with your genetics. Eating well, exercising regularly, and managing other health conditions can significantly lower your overall risk, even if you have a genetic predisposition.
3. I’m not European; does my ancestry change my stroke risk?
Section titled “3. I’m not European; does my ancestry change my stroke risk?”Yes, your ancestry can influence your genetic risk for conditions like cerebral ischemia. Many large genetic studies have focused on specific populations, often of European descent. This means that the identified genetic risk factors might differ for people from other ancestral backgrounds, and research is ongoing to understand these unique risks globally.
4. My sibling had a stroke, but I’m healthy. Why the difference?
Section titled “4. My sibling had a stroke, but I’m healthy. Why the difference?”Even with shared genetics, individual outcomes can vary widely. While you and your sibling share many genes, there are countless other genetic variants, each with small effects, along with unique environmental and lifestyle factors that contribute to overall risk. This complex interplay means that even close relatives can have different health experiences.
5. What do those “spots” on my brain scan mean for my risk?
Section titled “5. What do those “spots” on my brain scan mean for my risk?”Those “spots,” often called brain microbleeds (BMBs) or white matter hyperintensities (WMH), are markers of small vessel disease in the brain. They are linked to ischemic damage and can indicate a higher risk for future cerebrovascular events. Genetic factors are known to influence the presence and severity of these markers.
6. Could a genetic test really tell me my personal stroke risk?
Section titled “6. Could a genetic test really tell me my personal stroke risk?”Genetic tests can identify some specific genetic variants associated with an increased risk for cerebral ischemia. However, current research has only uncovered a moderate proportion of all the genetic factors involved. So, while a test can provide some insight, it won’t give you a complete picture of your total personal risk because many genetic influences are still unknown.
7. Why is predicting who gets a stroke so difficult, even with my family history?
Section titled “7. Why is predicting who gets a stroke so difficult, even with my family history?”Predicting stroke is complex because it’s influenced by many factors. While family history points to genetic predispositions, numerous genes with individually small effects contribute, alongside complex interactions with lifestyle, environmental factors, and other health conditions. This intricate web makes precise individual prediction challenging.
8. Does my age make my genetic risk for stroke more important?
Section titled “8. Does my age make my genetic risk for stroke more important?”Age is a significant, independent risk factor for stroke, and it often interacts with your genetic predispositions. While your genetic risk is present throughout life, the effects of certain genetic variants might become more pronounced or combine with age-related physiological changes to increase your risk as you get older.
9. Can regular exercise actually lower my genetic stroke risk?
Section titled “9. Can regular exercise actually lower my genetic stroke risk?”Yes, absolutely! Even if you have genetic predispositions, regular exercise is a powerful lifestyle factor that can significantly lower your risk. Exercise improves cardiovascular health, blood flow to the brain, and can help mitigate the impact of certain genetic vulnerabilities, promoting overall brain health.
10. Will genetics lead to new, personalized stroke treatments for me?
Section titled “10. Will genetics lead to new, personalized stroke treatments for me?”That’s a major goal of current research! By understanding the specific genetic underpinnings of cerebral ischemia, scientists aim to develop more personalized therapeutic approaches. This means future treatments could be tailored to your unique genetic profile, potentially leading to more effective prevention and recovery strategies.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Knol, M. J., et al. “Association of common genetic variants with brain microbleeds: A Genome-wide Association Study.” Neurology, 2020. PMID: 32913026.
[2] Ken-Dror, G. “Genome-wide association study identifies first locus associated with susceptibility to cerebral venous thrombosis.” Ann Neurol, 2021. PMID: 34459509.
[3] Brouwer, R. M., et al. “Genetic variants associated with longitudinal changes in brain structure across the lifespan.” Nat Neurosci, 2022. PMID: 35383335.
[4] Yan, Q., et al. “Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging.” Mol Psychiatry, 2018. PMID: 30361487.
[5] Ishigaki, K., et al. “Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases.” Nat Genet, 2020. PMID: 32514122.
[6] Alliey-Rodriguez, N., et al. “NRXN1 is associated with enlargement of the temporal horns of the lateral ventricles in psychosis.”Transl Psychiatry, 2019. PMID: 31530798.
[7] Choe, E. K., et al. “Leveraging deep phenotyping from health check-up cohort with 10,000 Korean individuals for phenome-wide association study of 136 traits.” Sci Rep, 2022. PMID: 35121771.
[8] Li, Q. S., et al. “Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level.” PLoS One, 2015. PMID: 26252872.
[9] Shadrin, A. A., et al. “Vertex-wise multivariate genome-wide association study identifies 780 unique genetic loci associated with cortical morphology.” Neuroimage, 2022. PMID: 34560273.
[10] Smith, S. M., et al. “An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank.” Nat Neurosci, 2021. PMID: 33875891.
[11] Makowski, C., et al. “Discovery of genomic loci of the human cerebral cortex using genetically informed brain atlases.” Science, 2022. PMID: 35113692.
[12] Sakaue, S., et al. “A cross-population atlas of genetic associations for 220 human phenotypes.” Nat Genet, 2021. PMID: 34594039.
[13] Katz, David H et al. “Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease.”Circulation, vol. 145, no. 1, 2022, pp. 1-13. PMID: 34814699.
[14] Pietzner, M et al. “Mapping the proteo-genomic convergence of human diseases.” Science, 7 Feb. 2023.
[15] Chung, J. et al. “Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer’s disease.”Alzheimers Res Ther, vol. 10, no. 1, 2018, p. 19.
[16] Bellenguez, C. et al. “Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke.”Nat Genet, vol. 44, no. 3, 2012, pp. 328-33.
[17] Ikram, M Arfan et al. “Heritability and genome-wide associations studies of cerebral blood flow in the general population.” J Cereb Blood Flow Metab, vol. 38, no. 9, 2018, pp. 1598-1608. PMID: 28627999.
[18] Shade, L. M., et al. “Genome-wide association study of brain arteriolosclerosis.” J Cereb Blood Flow Metab, vol. 42, no. 8, 2022, pp. 1437–1450. PMID: 35156446.
[19] Hofer, E et al. “Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults.” Nat Commun, 2020.
[20] Sun, BB et al. “Genomic atlas of the human plasma proteome.” Nature, 16 Aug. 2019.
[21] Yang, C et al. “Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders.” Nat Neurosci, 8 Jan. 2022.